Real-world evidence is more than just another way of tracking post-market patterns in drug utilization, said Maria Koehler, vice president of oncology strategy, innovation and collaborations at Pfizer Oncology.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
